German generic drugs and consumer healthcare products manufacturer STADA Arzneimittel has announced that it is now in the process of acquiring the pharmaceutical prescription and consumer health business of Biopharma, one of the leading Ukrainian pharmaceutical manufacturers in Ukraine.
”We see great potential in the Ukrainian market. With this acquisition, we will become an important player in the Ukrainian pharma market with a strong local production footprint,” STADA CEO Peter Goldschmidt said in a statement, adding that the transaction to buy Biopharma’s businesses will close in December.
“Stada’s acquisition of the pharmaceutical business of Biopharma is a logical step within Stada’s European growth strategy. We will integrate Ukraine as soon as possible into our European organization,” said Steffen Wagner, head of European Markets at Stada.
According to Biopharma’s managing partner Konstantin Efimenko, the company has been expanding rapidly since 2014, building two state-of-the-art, GMP-certified facilities in Bila Tserkva, Ukraine’s Kyiv region.
“We offer high-quality engineering, a skilled, professional team and high production standards monitored through international audits,” he continued, noting that attracting such a high-quality European investor demonstrates confidence in in Biopharma’s employees and capabilities, and will reinforce its ability to deliver high-quality and innovative products to patients.
Biopharma’s plasma processing business will be kept by the company’s shareholders who are expected to focus on its development both in Ukraine and abroad.